Cochlear Limited Navigates Modest Sales Growth Amidst Profit Dip and Innovative Product Launch
Cochlear Limited (ASX: COH), a global leader in hearing implant technology, has announced its financial results for the half-year ended December 2025, revealing a mixed performance. While the company achieved a modest 1% increase in sales revenue, reaching $1,176 million, its underlying net profit saw a decline of 9% to $195 million. Despite these figures, the board has declared an interim dividend of $2.15 per share, maintaining last year’s payout and representing a healthy 72% payout ratio.
Investors have been closely watching Cochlear’s performance, particularly in light of its significant investment in innovation and market expansion. The company’s latest financial update highlights key figures that paint a comprehensive picture of its operational and financial standing.
Key Financial Highlights for the Half-Year Ended December 2025:
- Sales Revenue: An increase of 1% to $1,176 million. However, when adjusted for currency fluctuations (constant currency), this represents a 2% decrease.
- Underlying Net Profit: A notable drop of 9% to $194.8 million.
- Statutory Net Profit: Experienced a more significant decline of 21% to $161.5 million.
- Underlying Earnings Per Share (EPS): Decreased by 9% to $2.98.
- Interim Dividend: Maintained at $2.15 per share, reflecting a 72% payout ratio and an 85% franking credit.
- Operating Cash Flow: Showed an increase, reaching $136.8 million.
- Free Cash Flow: Also saw an upward trend, climbing to $82.7 million.
Strategic Developments and Market Dynamics:
A significant development for Cochlear during this period was the launch of the Nucleus Nexa System. Hailed as the world’s first upgradeable smart cochlear implant, this groundbreaking device is the culmination of 20 years of dedicated research and development. The Nexa System has been met with strong market reception, quickly becoming a dominant force in sales. In December alone, it accounted for an impressive 80% of all implant sales.
However, the initial rollout of the Nexa System faced some headwinds. The complex processes of registration and contract renewal, particularly in the early stages, led to a delay in the full momentum of the new system in the first half of the financial year.
The company also observed growth in emerging markets, where cochlear implant unit sales saw a 6% increase. Despite this unit growth, revenue in these regions remained flat. This was attributed to a higher proportion of lower-priced devices being sold, with a particular emphasis on the Chinese market.
In other segments, Cochlear’s services revenue experienced a steady climb of 2%, while its Acoustics revenue remained consistent. The company has continued its commitment to future growth by increasing its investment in research and development (R&D) by 9%. Furthermore, Cochlear has been actively building its inventory, which has contributed to an increase in working capital.
Management’s Outlook and Confidence:
Dig Howitt, CEO and President of Cochlear, expressed confidence in the company’s long-term prospects. He highlighted the substantial and unmet clinical need for both cochlear and acoustic implants, which he believes will continue to be a key driver for sustainable business growth.
“We remain confident of the opportunity to grow our markets,” Howitt stated. “There remains a significant, unmet and addressable clinical need for cochlear and acoustic implants that is expected to continue to underpin the long-term sustainable growth of the business.”
Looking Ahead: The Second Half and Beyond:
Cochlear anticipates a stronger performance in the second half of the financial year. This optimism is fuelled by several factors:
- The full impact of the Nexa System’s availability and wider adoption.
- Increased uptake of services.
- An expected improvement in Acoustics performance.
Despite these positive indicators, management has forecast the underlying net profit for the full fiscal year 2026 to be at the lower end of the projected range of $435 million to $460 million. This revised forecast reflects the slower-than-anticipated contracting process for the Nexa System.
Cochlear’s dividend policy remains steadfast, targeting a 70% payout of underlying net profit. The company is also committed to continued investment in both R&D and capacity expansion to support future growth. Foreign exchange rate fluctuations are expected to play a role in profit levels in the coming months and will be closely monitored.
Shareholder Performance:
Over the past 12 months, Cochlear’s share price has seen a decline of 19%. This performance lags behind the broader market, with the S&P/ASX 200 Index (ASX: XJO) experiencing a rise of 6% during the same period. This divergence underscores the specific market and company-specific factors influencing Cochlear’s valuation.
